271 related articles for article (PubMed ID: 30149765)
1. Chimeric antigen receptor T-cell therapy hits the market.
Boyer MW
Immunotherapy; 2018 Aug; 10(11):911-912. PubMed ID: 30149765
[No Abstract] [Full Text] [Related]
2. Chimeric Antigen Receptor T-Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside.
Rodriguez-Cartagena LG; Bowles BS; Kurani SS; Windebank AJ; Kenderian SS; Greenberg-Worisek AJ
Clin Transl Sci; 2018 Nov; 11(6):537-539. PubMed ID: 30242965
[No Abstract] [Full Text] [Related]
3. Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.
Myers RM; Dolan J; Teachey DT
Expert Rev Clin Immunol; 2020 Oct; 16(10):1029-1042. PubMed ID: 32975147
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies.
Cao JX; Gao WJ; You J; Wu LH; Liu JL; Wang ZX
Cytotherapy; 2019 Jul; 21(7):769-781. PubMed ID: 31160157
[TBL] [Abstract][Full Text] [Related]
5. HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation.
Jin X; Cao Y; Wang L; Sun R; Cheng L; He X; Xiao X; Jiang Y; Li Q; Zhang H; Lu W; Lyu C; Jiang Y; Meng J; Zhao M
Leukemia; 2020 Mar; 34(3):909-913. PubMed ID: 31628429
[No Abstract] [Full Text] [Related]
6. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
Mohty M; Gautier J; Malard F; Aljurf M; Bazarbachi A; Chabannon C; Kharfan-Dabaja MA; Savani BN; Huang H; Kenderian S; Nagler A; Perales MA
Leukemia; 2019 Dec; 33(12):2767-2778. PubMed ID: 31690821
[TBL] [Abstract][Full Text] [Related]
7. Updates on CAR T-cell therapy in B-cell malignancies.
Jacoby E; Shahani SA; Shah NN
Immunol Rev; 2019 Jul; 290(1):39-59. PubMed ID: 31355492
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.
Yoo HJ; Liu Y; Wang L; Schubert ML; Hoffmann JM; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Mokhir A; Schmitt M; Sellner L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31109083
[TBL] [Abstract][Full Text] [Related]
9. CARTs to the rescue: therapeutic potential of chimeric antigen receptor T-cells in patients with B-cell malignancies.
Tam CS
Leuk Lymphoma; 2013 Feb; 54(2):215-6. PubMed ID: 22950939
[No Abstract] [Full Text] [Related]
10. Generation of CD19-Targeted Chimeric Antigen Receptor T Cells.
Kiani J; Naderi M; Torabi-Rahvar M; Ranjbar A; Aghayan HR; Janzamin E; Ahmadbeigi N
Arch Iran Med; 2019 Jan; 22(1):7-10. PubMed ID: 30821155
[TBL] [Abstract][Full Text] [Related]
11. Universal CAR T Cells Treat Leukemia.
Cancer Discov; 2017 Apr; 7(4):342. PubMed ID: 28193774
[TBL] [Abstract][Full Text] [Related]
12. CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond.
Quintás-Cardama A
Leuk Lymphoma; 2019 May; 60(5):1346-1348. PubMed ID: 30646790
[No Abstract] [Full Text] [Related]
13. 'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors.
Gilham DE; Maher J
Immunotherapy; 2017 Aug; 9(9):723-733. PubMed ID: 28771104
[TBL] [Abstract][Full Text] [Related]
14. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.
Brentjens RJ; Rivière I; Park JH; Davila ML; Wang X; Stefanski J; Taylor C; Yeh R; Bartido S; Borquez-Ojeda O; Olszewska M; Bernal Y; Pegram H; Przybylowski M; Hollyman D; Usachenko Y; Pirraglia D; Hosey J; Santos E; Halton E; Maslak P; Scheinberg D; Jurcic J; Heaney M; Heller G; Frattini M; Sadelain M
Blood; 2011 Nov; 118(18):4817-28. PubMed ID: 21849486
[TBL] [Abstract][Full Text] [Related]
15. Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia.
Turazzi N; Fazio G; Rossi V; Rolink A; Cazzaniga G; Biondi A; Magnani CF; Biagi E
Br J Haematol; 2018 Sep; 182(6):939-943. PubMed ID: 28832950
[No Abstract] [Full Text] [Related]
16. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
17. "Off-the-Shelf" CAR T-Cell Therapy Tested in Pediatric B-Cell Leukemia.
Larkin H
JAMA; 2022 Dec; 328(22):2201. PubMed ID: 36511937
[No Abstract] [Full Text] [Related]
18. Safer CAR T-Cell Therapy.
Abbasi J
JAMA; 2019 Jun; 321(22):2155. PubMed ID: 31184718
[No Abstract] [Full Text] [Related]
19. Infusion of chimeric antigen receptor T cells against dual targets of CD19 and B-cell maturation antigen for the treatment of refractory multiple myeloma.
Tang F; Lu Y; Ge Y; Shang J; Zhu X
J Int Med Res; 2020 Jan; 48(1):300060519893496. PubMed ID: 31939323
[TBL] [Abstract][Full Text] [Related]
20. [Not Available].
Gauthier J
Bull Cancer; 2018 Dec; 105 Suppl 2():S214-S217. PubMed ID: 30686360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
